Literature DB >> 12806570

Omeprazole reduces clozapine plasma concentrations. A case report.

A Frick, J Kopitz, N Bergemann.   

Abstract

A number of interactions of the atypical antipsychotic clozapine with other drugs are well known, some of which can be attributed in part to the pharmacokinetic interactions associated with cytochrome P450 enzymes during drug metabolism. Clozapine is mainly metabolized by the cytochrome P450 isoenzyme 1A2. The proton pump inhibitor omeprazole can induce CYP1A2. We report on two patients with schizoaffective disorder who received omeprazole in addition to clozapine because of gastrointestinal complaints. Before the co-medication with omeprazole was started, the patients had been receiving clozapine for 78 and 41 days and for 40 and 8 days at a stable daily dose of 325 mg (patients 1 and 2, respectively). The co-medication with omeprazole was associated with a reduction in the plasma levels of clozapine of 41.9 % and 44.7 %, respectively, in these patients. The decrease in the plasma concentrations of clozapine in the presence of omeprazole might be due to the induction of the cytochrome P450 isoenzyme CYP1A2. If patients are receiving omeprazole as co-medication, close monitoring of plasma clozapine levels is recommended. If clozapine levels drop, the drug should be adjusted accordingly. If necessary, an alternative to omeprazole should be chosen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12806570     DOI: 10.1055/s-2003-39980

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  9 in total

1.  Confounding factors for variation of clozapine plasma levels: drug interactions with proton pump inhibitor or infectious etiologies?

Authors:  Sophie Wagner; M G Varet-Legros; Claudine Fabre; Jean Louis Montastruc; Haleh Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2010-11-06       Impact factor: 2.953

Review 2.  Clinically significant drug interactions with atypical antipsychotics.

Authors:  William Klugh Kennedy; Michael W Jann; Eric C Kutscher
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

3.  Elevated clozapine serum levels in combination with perazine.

Authors:  M Fischer; S Unterecker; J Deckert; B Pfuhlmann
Journal:  Psychopharmacology (Berl)       Date:  2013-02-09       Impact factor: 4.530

Review 4.  Clozapine in primary care.

Authors:  Karl Winckel; Dan Siskind
Journal:  Aust Prescr       Date:  2017-12-04

5.  Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.

Authors:  Maxim Kuzin; Georgios Schoretsanitis; Ekkehard Haen; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Michael Paulzen
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

Review 6.  Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

Authors:  Quan Zhou; Xiao-Feng Yan; Zhong-Miao Zhang; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

7.  The Value of Desmethylclozapine and Serum CRP in Clozapine Toxicity: A Case Report.

Authors:  Khalid Abou Farha; Andre van Vliet; Henderikus Knegtering; Richard Bruggeman
Journal:  Case Rep Psychiatry       Date:  2012-08-15

8.  Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management.

Authors:  Wei Li; Su Zeng; Lu-Shan Yu; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2013-05-27       Impact factor: 2.423

Review 9.  Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes.

Authors:  Florian Klomp; Christoph Wenzel; Marek Drozdzik; Stefan Oswald
Journal:  Pharmaceutics       Date:  2020-12-11       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.